Novartis opens pitch for global brand launch
Novartis, the pharmaceutical giant, is searching for a global advertising agency to handle the international roll-out of an over-the-counter product.
An RFI has been issued to a number of agencies, including UK-based shops, from the Denmark-based intermediary Hestbaek Consult. The brief, dubbed "Project Cool", covers the provision of advertising to support the launch of a product, which is not named in the RFI, across markets in regions including Europe, the US and Asia.
Novartis, which has its headquarters in Basel, Switzerland and has a presence in more than 140 countries, will require the appointed agency to target consumers as well as healthcare professionals.
Agency sources have speculated that the brief relates to a wider roll-out of the Novartis US pain-relief brand Excedrin. They said Excedrin, which spends around $45 million on US advertising, could be set for a global launch that will require a positive brand awareness campaign following a product recall in the US this year.
Novartis works with a number of agencies including DraftFCB London, Wunderman Switzerland and Grey Group.
This article was first published on campaignlive.co.uk
- Campaign Marketing Manager EMAP Competitive + Bonus, London (Greater) / London (East), London (Greater)
- Exhibition Designers WRG Live Competitive salary and benefits package dependant upon experience, Manchester, Greater Manchester
- Producer WRG Live Competitve salary and benefits package dependent upon experience, London (Central), London (Greater) / Manchester, Greater Manchester
- Content Manager WRG Live Competitive salary and benefits package, Manchester, Greater Manchester
- Marketing Manager (Mobile and Social) Creative Recruitment £40000 - £50000 per annum, London
- Martin Sorrell earns 780 times more than average WPP employee
- 3 top tips on how to save an epic social media fail
- Lake Capital rejects demands of Engine's rebel shareholders
- Head lice-killing mousse launches in the UK with cartoon campaign
- Facebook's 'Buy' button: a leap too far?
- Beiersdorf postpones review after MAA criticisms of procedure